JB BACHET
JB BACHET
Afiliación desconocida
Dirección de correo verificada de aphp.fr
Título
Citado por
Citado por
Año
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
T Conroy, F Desseigne, M Ychou, O Bouché, R Guimbaud, Y Bécouarn, ...
New England Journal of Medicine 364 (19), 1817-1825, 2011
55082011
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lievre, JB Bachet, D Le Corre, V Boige, B Landi, JF Emile, JF Côté, ...
Cancer research 66 (8), 3992-3995, 2006
24772006
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
A Lievre, JB Bachet, V Boige, A Cayre, D Le Corre, E Buc, M Ychou, ...
Journal of clinical oncology 26 (3), 374-379, 2008
17852008
FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer
T Conroy, P Hammel, M Hebbar, M Ben Abdelghani, AC Wei, JL Raoul, ...
New England Journal of Medicine 379 (25), 2395-2406, 2018
8352018
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
P Laurent-Puig, A Cayre, G Manceau, E Buc, JB Bachet, T Lecomte, ...
Journal of clinical oncology 27 (35), 5924-5930, 2009
7832009
Pancreatic adenocarcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
T Seufferlein, JB Bachet, E Van Cutsem, P Rougier
Annals of oncology 23, vii33-vii40, 2012
3832012
Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter …
C Tournigand, T André, F Bonnetain, B Chibaudel, G Lledo, T Hickish, ...
Journal of clinical oncology 30 (27), 3353-3360, 2012
3242012
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma
R Maréchal, JB Bachet, JR Mackey, C Dalban, P Demetter, K Graham, ...
Gastroenterology 143 (3), 664-674. e6, 2012
2252012
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial
FC Bidard, F Huguet, C Louvet, L Mineur, O Bouche, B Chibaudel, P Artru, ...
Annals of oncology 24 (8), 2057-2061, 2013
1642013
Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features
F Puleo, R Nicolle, Y Blum, J Cros, L Marisa, P Demetter, E Quertinmont, ...
Gastroenterology 155 (6), 1999-2013. e3, 2018
1582018
Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker
D Pietrasz, N Pécuchet, F Garlan, A Didelot, O Dubreuil, S Doat, ...
Clinical Cancer Research 23 (1), 116-123, 2017
1522017
Unicancer GI PRODIGE 24/CCTG PA. 6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected …
T Conroy, P Hammel, M Hebbar, M Ben Abdelghani, AC Wei, JL Raoul, ...
Journal of Clinical Oncology 36 (18_suppl), LBA4001-LBA4001, 2018
1422018
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort
L Marthey, A Sa-Cunha, JF Blanc, M Gauthier, A Cueff, E Francois, ...
Annals of surgical oncology 22 (1), 295-301, 2015
1302015
Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness
J Leca, S Martinez, S Lac, J Nigri, V Secq, M Rubis, C Bressy, A Sergé, ...
The Journal of clinical investigation 126 (11), 4140-4156, 2016
1252016
Current standards and new innovative approaches for treatment of pancreatic cancer
T Conroy, JB Bachet, A Ayav, F Huguet, A Lambert, C Caramella, ...
European Journal of Cancer 57, 10-22, 2016
1212016
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
A Portal, S Pernot, D Tougeron, C Arbaud, AT Bidault, ...
British journal of cancer 113 (7), 989-995, 2015
1212015
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and …
T André, H Blons, M Mabro, B Chibaudel, JB Bachet, C Tournigand, ...
Annals of oncology 24 (2), 412-419, 2013
932013
RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study
JB Bachet, O Bouché, J Taieb, O Dubreuil, ML Garcia, A Meurisse, ...
Annals of Oncology 29 (5), 1211-1219, 2018
912018
Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label …
T André, D Vernerey, L Mineur, J Bennouna, J Desrame, R Faroux, ...
Journal of clinical oncology 36 (15), 1469-1477, 2018
902018
Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer
T Conroy, P Hammel, M Hebbar, M Ben Abdelghani, AC Wei, JL Raoul, ...
N Engl J Med 379 (25), 2395-2406, 2018
892018
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20